- Home
- FCAP vs MSLE Comparison
FCAP vs MSLE Comparison
Compare FCAP & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FCAP | MSLE |
|---|---|---|
| Founded | 1891 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.1M | 186.9M |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FCAP | MSLE |
|---|---|---|
| Price | $62.55 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.17 |
| AVG Volume (30 Days) | 15.0K | ★ 64.2K |
| Earning Date | 11-03-2026 | 11-15-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 36.97 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $7,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.47 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $41.63 | $5.44 |
| 52 Week High | $71.00 | $13.39 |
Technical Indicators
Market Signals| Indicator | FCAP | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 32.08 |
| Support Level | $62.07 | $5.52 |
| Resistance Level | $64.43 | $10.58 |
| Average True Range (ATR) | 1.77 | 0.58 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 60.98 | 7.39 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.